ARK's Cathie Wood Dumps More Twitter Stock, Buys $20M in Fate Therapeutics Stock

Zinger Key Points
  • Wood's Ark Investment Management has sold 1,451 shares of Twitter.
  • Fate Therapeutics is the 21st largest holding in Ark Innovation ETF, the firm’s flagship fund.

Cathie Wood-led Ark Investment Management has bought 628,060 shares of clinical-stage biopharmaceutical company Fate Therapeutics Inc. FATE through two of the firm’s exchange-traded funds (ETF) valued at over $20 million based on Thursday’s closing price.

Fate Therapeutics is the 21st largest holding in Ark Innovation ETF ARKK, the firm’s flagship fund, with a weight of 2.08%. The fund holds over 6.5 million shares of the firm valued at over $211 million, according to its website.

Also Read: Alibaba Holds It Together, EV Stocks Shine As Wider Hang Seng Falls: Key Events Driving Hong Kong Stocks Today

The stock has gained over 9% in a month. Fate Therapeutics recently reported revenues of $18.5 million for the second quarter of 2022. Its earnings per share stood at $-0.79 against the estimate of $-0.82 according to Benzinga Pro.

Twitter share sale: Ark Investment Management has sold 1,451 shares of Twitter Inc TWTR valued at over $63,000 via two of its funds.

Other Major Trades: Cathie Wood also bought 100,852 shares of Teladoc Health Inc TDOC valued at over $3.8 million via four of the firm’s funds. Wood sold over 1.3 million shares of Compugen Ltd. CGEN valued at over $1.9 million through two of the firm’s funds.

 

 

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Long IdeasNewsPenny StocksBroad U.S. Equity ETFsShort IdeasMarketsTrading IdeasETFsCathie WoodEurasia
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!